RxDoctor Payments Data

Bernard D'souza

Hospitalist · Waterbury, CTNPI 1104098789

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $145 and has fallen 73.4% since, to $38 in 2025.

$551in general payments, 2019–2025

Across 27 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$128
  • Johnson & Johnson$124
  • Pfizer$77
  • AstraZeneca$69
  • Abbott$45
  • Mylan Specialty L.p.$43
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$551100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$551 in reported general payments places this provider in the 80th percentile of 349 hospitalist providers in Connecticut.

See all hospitalist providers in Connecticut

Medicare billing

Part B allowed, 2024
$69,215
Medicare patients
207
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$7,699
Cefpodoxime Proxetil26$653
Levetiracetam12$156
Pantoprazole Sodium19$106
Metoprolol Succinate15$75
Prednisone27$73
Atorvastatin Calcium19$72
Furosemide23$63
Carvedilol13$48
Amlodipine Besylate20$36
Losartan Potassium12$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$7,69912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 349 hospitalist providers in Connecticut.

Other hospitalist in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →